We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Meldex | LSE:MDX | London | Ordinary Share | GB0032681628 | ORD 1P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 7.09 | 0.00 | 01:00:00 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| 0 | 0 | N/A | 0 |
Hot Features
Premium
RNS Number : 8834F
Meldex International PLC
15 October 2008
For Immediate Release 15 October 2008
Meldex International plc
("Meldex", or "the Company")
Licensing Agreement for Rocgel
The Company is pleased to report that it has signed an agreement to license/distribute Rocgel, into several North African countries as
well as Vietnam. The agreement, dated 14 October 2008, gives the licensee the rights to sell Rocgel, an antacid for the treatment of
oesophageal, gastric and duodenal conditions. Meldex will receive EUR0.6m from this agreement.
As announced with the interim results on 30 September 2008, the Company remains in discussions to increase its working capital
facilities. The Company is in advanced stages of dialogue with multiple providers of capital, and will update the market shortly.
For further information:
Buchanan Communications + 44 (0) 20 7466 5000
Rebecca Skye Dietrich
FinnCap, NOMAD + 44 (0) 20 7600 1658
Geoff Nash
This information is provided by RNS
The company news service from the London Stock Exchange
END
AGRFGMMGLKRGRZG
1 Year Meldex Chart |
1 Month Meldex Chart |
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
